<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04760327</url>
  </required_header>
  <id_info>
    <org_study_id>0120-692/2017/4</org_study_id>
    <nct_id>NCT04760327</nct_id>
  </id_info>
  <brief_title>Electrochemotherapy of Gynecological Cancers</brief_title>
  <acronym>GynECT</acronym>
  <official_title>Electrochemotherapy of Gynecological Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Oncology Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Oncology Ljubljana</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effectiveness, feasibility and safety of electrochemotherapy in treatment of&#xD;
      local and/or regional recurrences of gynecological cancers with electrochemotherapy in which&#xD;
      standard treatment options have been exhausted.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of electrochemotherapy according to RECIST 1.1 criteria.</measure>
    <time_frame>Changes from baseline regularly up to 24 months</time_frame>
    <description>Effectiveness of electrochemotherapy in the treatment of local or regional recurrences of gynecological tumors in which standard treatment options have been exhausted. Effectiveness will be evaluated according to RECIST 1.1 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of electrochemotherapy according to CTCAE v5.0 criteria.</measure>
    <time_frame>during hospitalization and up to 24 months</time_frame>
    <description>To determine safety of electrochemotherapy in the treatment of local or regional recurrences of gynecological tumors in which standard treatment options have been exhausted. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 criteria will be determined.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gynecological Cancers</condition>
  <arm_group>
    <arm_group_label>Electrochemotherapy of gynecological cancers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Electrochemotherapy with bleomycin or cisplatin</intervention_name>
    <description>Electrochemotherapy with cisplatin or bleomycin of gynecological cancers</description>
    <arm_group_label>Electrochemotherapy of gynecological cancers</arm_group_label>
    <other_name>Combination of drug delivery platform (electroporation) and drug (bleomycin or cisplatin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Local or regional relapse of gynecological tumors in which standard treatment options&#xD;
             have been exhausted.&#xD;
&#xD;
          2. Age more than 18.&#xD;
&#xD;
          3. Life expectancy more than 3 month.&#xD;
&#xD;
          4. Performance status Karnofsky ≥ 70 or WHO &lt; or 2.&#xD;
&#xD;
          5. Treatment free interval minimum 2 weeks.&#xD;
&#xD;
          6. Patient must be mentally capable of understanding the given information and regarding&#xD;
             treatment and any adverse reactions that may occur during treatment.&#xD;
&#xD;
          7. Patient must give informed consent.&#xD;
&#xD;
          8. Patient must be discussed at the multidisciplinary team before entering the trial.&#xD;
&#xD;
          9. Patient should be suitable for anesthesia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Visceral, bone or diffuse metastases.&#xD;
&#xD;
          2. Life-threatening infection and/or heart failure and/or liver failure and/or other&#xD;
             severe systemic pathologies.&#xD;
&#xD;
          3. Significant reduction in respiratory function.&#xD;
&#xD;
          4. Age less than 18 years.&#xD;
&#xD;
          5. Coagulation disturbances (those who do not respond on standard treatment with&#xD;
             vitamin-K or fresh frozen plasma).&#xD;
&#xD;
          6. Cumulative dose of ≥ 400 mg/m2 bleomycin received.&#xD;
&#xD;
          7. Impaired kidney function (creatinin &gt; 150 µmol/l).&#xD;
&#xD;
          8. Patients with epilepsy.&#xD;
&#xD;
          9. Pregnancy.&#xD;
&#xD;
         10. Patient incapable of understanding the aim of the study or disagree with the entering&#xD;
             into the clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>105 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gregor Serša, PhD</last_name>
    <phone>+386 1 5879 434</phone>
    <email>gsersa@onko-i.si</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maja Čemažar, PhD</last_name>
    <phone>+386 1 5879 544</phone>
    <email>mcemazar@onko-i.si</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of oncology Ljubljna</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregor Sersa, PhD</last_name>
      <phone>+386-1-5879-544</phone>
      <email>gsersa@onko-i.si</email>
    </contact>
    <contact_backup>
      <last_name>Maja Cemazar, PhD</last_name>
      <email>mcemazar@onko-i.si</email>
    </contact_backup>
    <investigator>
      <last_name>Barbara Šegedin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helena Barbara Zobec Logar, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manja Šešek, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregor Serša, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maja Čemažar, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maša Bošnjak, MPharm, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tjaša Pečnik, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 5, 2018</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electrochemotherapy</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Bleomycin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

